
Sothema realized a consolidated revenue of 940 million dirhams in the third quarter of 2026, up 24% over one year, according to the indicators that the laboratory published on Tuesday, November 17.
Over the first nine months, its sales reach 2.736 billion dirhams, in progression of 19%. The group attributes them to its historical activities in cardiology, in diabetology and in ophthalmology, as well as to the oncology of Axess Pharma and to the dialysis solutions of Soludia.
In Morocco, Sothema obtained a marketing authorization for a cannabidiol-based treatment against pediatric epilepsy. It also filed a dossier for an association of cannabidiol and THC intended for multiple sclerosis.
Its investments reach 130 million dirhams at the end of September, against 49 million one year earlier, devoted notably to its industrial capacities and to the purchase of the rights of the Cialis brand in Morocco.
The consolidated net debt, for its part, falls by 9% compared with the end of 2025, to 758 million dirhams.
Photo: Sothema.




